Finanzen von Protalix Biotherapeutics Inc (PLX)PLXProtalix Biotherapeutics Inc

Evaluating the bottom line, Protalix BioTherapeutics, Inc. maintains a gross margin of 60.99%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.48%, while the net margin is 18.98%. These profitability ratios, combined with a Return on Equity (ROE) of 31.23%, provide a clear picture of how effectively PLX converts its operational activities into shareholder value.

In the context of the broader market, PLX competes directly with industry leaders such as KRRO and MSLE. With a market capitalization of $216.73M, it holds a significant position in the sector. When comparing efficiency, PLX's gross margin of 60.99% stands against KRRO's N/A and MSLE's N/A. Such benchmarking helps identify whether Protalix BioTherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Protalix has shown significant revenue growth, with Q1 2026 revenue reported at $33.8 million, a 233.8% increase year-over-year. The gross margin for Q1 2026 was an impressive 87.77%, indicating strong profitability potential. The net margin for the same quarter was 54.27%, showcasing effective cost management and operational efficiency.